Bristol OTC Stock Today

BMYMP -  USA Stock  

USD 2,000  0.00  0.00%

Market Performance
14 of 100
Odds Of Distress
Less than 33
Bristol Myer is selling at 2000.00 as of the 7th of December 2021; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 2000.0. Bristol Myer has about a 33 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for Bristol Myer Squi are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of November 2021 and ending today, the 7th of December 2021. Click here to learn more.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. The company has 1.64 B outstanding shares of which 10 shares are currently shorted by private and institutional investors with about 0.59 days to cover all short positions. More on Bristol Myer Squi
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Bristol Myer OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Bristol Myer's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bristol Myer or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Bristol Myer Squi is way too risky over 90 days horizon
Bristol Myer Squi appears to be risky and price may revert if volatility continues
On 8th of November 2021 Bristol Myer paid $ 0.5 per share dividend to its current shareholders
Latest headline from www.news-journal.com: CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY - Longview News-Journal
Legal NameBristol Myer Squi
CEO, DirectorLamberto Andreotti  (View All)
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Bristol Myer's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldOvervalued
Bristol Myer Squi [BMYMP] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Mega-Cap' category with current market capitalization of 3280 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bristol Myer's market, we take the total number of its shares issued and multiply it by Bristol Myer's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Bristol Myer Squi classifies itself under Healthcare sector and is part of Drug Manufacturers - Major industry. The entity has 1.64 B outstanding shares of which 10 shares are currently shorted by private and institutional investors with about 0.59 days to cover all short positions. Bristol Myer Squi has accumulated about 6.07 B in cash with 5.06 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72.
Check Bristol Myer Probability Of Bankruptcy

Bristol Stock Price Odds Analysis

What are Bristol Myer's target price odds to finish over the current price? Contingent on a normal probability distribution, the odds of Bristol Myer jumping above the current price in 90 days from now is about 6.98%. The Bristol Myer Squi probability density function shows the probability of Bristol Myer otc stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Bristol Myer has a beta of 0.9875 suggesting Bristol Myer Squi market returns are highly reactive to returns on the market. As the market goes up or down, Bristol Myer is expected to follow. Moreover, the company has an alpha of 1.4503, implying that it can generate a 1.45 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 2000.0HorizonTargetOdds Up 2000.0 
92.99%90 days
 2,000 
6.98%
Based on a normal probability distribution, the odds of Bristol Myer to move above the current price in 90 days from now is about 6.98 (This Bristol Myer Squi probability density function shows the probability of Bristol OTC Stock to fall within a particular range of prices over 90 days) .

Bristol Myer Squi Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bristol Myer market risk premium is the additional return an investor will receive from holding Bristol Myer long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bristol Myer. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Bristol Myer's alpha and beta are two of the key measurements used to evaluate Bristol Myer's performance over the market, the standard measures of volatility play an important role as well.

Bristol Stock Against Markets

Picking the right benchmark for Bristol Myer otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bristol Myer otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bristol Myer is critical whether you are bullish or bearish towards Bristol Myer Squi at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bristol Myer without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Tickers Now

   

Stock Tickers

Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
All  Next Launch Module

Bristol Myer Corporate Directors

Bristol Myer corporate directors refer to members of a Bristol Myer board of directors. The board of directors generally takes responsibility for the Bristol Myer's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Bristol Myer's board members must vote for the resolution. The Bristol Myer board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Togo West - Independent DirectorProfile
Karen Vousden - DirectorProfile
Alan Lacy - Independent DirectorProfile
Robert Bertolini - Independent DirectorProfile
Continue to Trending Equities. Note that the Bristol Myer Squi information on this page should be used as a complementary analysis to other Bristol Myer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Bristol OTC Stock analysis

When running Bristol Myer Squi price analysis, check to measure Bristol Myer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myer is operating at the current time. Most of Bristol Myer's value examination focuses on studying past and present price action to predict the probability of Bristol Myer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol Myer's price. Additionally, you may evaluate how the addition of Bristol Myer to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Bristol Myer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myer. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bristol Myer Squi is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myer's value that differs from its market value or its book value, called intrinsic value, which is Bristol Myer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myer's market value can be influenced by many factors that don't directly affect Bristol Myer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myer's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol Myer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.